Announcements Trials
Browse Landscape

Phase

Phase NA 11Phase 1 11Phase 2 9Phase EARLY_PHASE1 5Phase 1/2 4Phase 3 3Phase 4 1Phase 2/3 1

Status

Completed 145Terminated 59Recruiting 47Unknown 46Withdrawn 21Active not recruiting 16Not yet recruiting 4Suspended 2

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 3Plasma cell 2

Conditions

Breast Neoplasms 24Colorectal Neoplasms 19Carcinoma, Non-Small-Cell Lung 19Neoplasms 18Recurrence 16Pancreatic Neoplasms 16Multiple Myeloma 15Prostatic Neoplasms 13Advanced Solid Tumors 12Carcinoma, Hepatocellular 11Stomach Neoplasms 10Leukemia, Myeloid, Acute 10Advanced Solid Tumor 10Ovarian Neoplasms 9Triple Negative Breast Neoplasms 8Small Cell Lung Carcinoma 7Squamous Cell Carcinoma of Head and Neck 6Neoplasm Metastasis 6Melanoma 6Lymphoma, Large B-Cell, Diffuse 6Head and Neck Neoplasms 6Glioblastoma 6Urinary Bladder Neoplasms 5Solid Tumors 5Lymphoma, B-Cell 5Lung Neoplasms 5Liver Neoplasms 5Glioma 5Uterine Cervical Neoplasms 4Lymphoma 4

Interventions

Injections 1Immunotherapy, Adoptive 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Not yet recruiting × Lymphoma × Clear all
NCT07333469 2026-01-13

A Clinical Study of HX111 in Patients With Advanced Solid Tumor and Lymphoma

Hanx Biopharmaceuticals (Wuhan) Co., Ltd.

Phase 1/2 Not yet recruiting
70 enrolled
Lymphoid

Lymphoma

NCT07107204 2025-09-17

A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies

Biotroy Therapeutics

Phase 1/2 Not yet recruiting
116 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Recurrence, Hematologic Neoplasms

NCT07020260 2025-06-13

PACMAN

Princess Maxima Center for Pediatric Oncology

Phase 1/2 Not yet recruiting
18 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Lymphoma

NCT05055791 2021-09-24

A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 1/2 Not yet recruiting
312 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡